Comprehensive diligence around a target at the start of a discovery program can make the difference between success and failure. Learn how Syngene’s Target Assessment service enables informed decision-making resulting in increased clinical and commercial success.

Learn about Syngene’s expertise in  Safety/Tox studies that allows us to guide you through the various requirements leading to successful IND submission.

Learn the DMPK strategies that have helped Syngene scientists avoid drug development mistakes early while driving cost-effective, reproducible, high-quality data for clients.

Syngene offers expertise in all aspects of PROTACs – from designing of small molecules to their synthesis, lead optimization, and ultimate candidate delivery at an accelerated pace.

Learn how Syngene achieves manufacturing milestones in Biologics using a systemic approach to 100% ‘first-time right’ technology transfer.

How and why CROs/CDMOs are better positioned to bridge the gap between vaccine demand and supply, safely and at speed.

Syngene is using virtual audits to enable clients/regulators experience its capability and infrastructure, without physically visiting the site.

Synthetic oligonucleotides have emerged as an important modality for diagnostics and potential therapy option for COVID-19.

Antisense Oligonucleotides is gaining momentum as a treatment modality to correct faulty protein expression by non-conventional means i.e., splicing modifications.

At Syngene, we have developed a roadmap across pre-IND, IND and NDA that seamlessly integrate the various pre-clinical studies — thereby accelerating the initiation of Clinical trials.